Microcap Ledger Onconetix, Inc. $ONCO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cincinnati, OH
- Fiscal year end
- December 31
- Shares outstanding
- 3,949,107 [10-Q 2026-08-13]
What the company doesAI summary of filing
Onconetix is a commercial-stage biotechnology company focused on men's health and oncology. The company's primary product is Proclarix, an in vitro diagnostic blood test for prostate cancer that is CE-marked and approved for sale in the European Union and is being developed for the U.S. market through a license agreement with LabCorp. Onconetix generates revenue from Proclarix sales in Europe, which totaled $23,091 in 2025. The company previously acquired ENTADFI, an FDA-approved prostate treatment, but abandoned its commercialization in 2024 due to resource constraints and cash limitations. Onconetix has incurred net losses since inception and faces substantial doubt about its ability to continue as a going concern. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $38.6K | −$7.08M | −$4.04M | $5.94M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $815.4K | −$14.03M | −$9.68M | $5.22M | [10-K 2026-03-13] |
| FY ended Dec 2024 | $2.52M | −$58.69M | −$10.50M | $646.5K | [10-K 2026-03-13] |
- Quarterly cash burn
- −$2.02M
- Cash runway Estimate
- ~8.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-12-05 | 8,294,734 | [10-Q 2024-12-10] |
| 2025-05-30 | 44,358,422 | [10-K 2025-06-02] |
| 2025-06-12 | 44,358,422 | [10-Q 2025-06-12] |
| 2025-08-13 | 1,545,704 | [10-Q 2025-08-14] |
| 2025-11-12 | 1,560,668 | [10-Q 2025-11-13] |
| 2026-03-11 | 3,584,245 | [10-K 2026-03-13] |
| 2026-05-12 | 11,464,572 | [10-Q 2026-05-13] |
| 2026-08-13 | 3,949,107 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-08-12; declared effective 2026-09-03 [S-1 2026-08-12]
Listing status
Current status: 5 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-05-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-05-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-22] |
| 2025-04-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-30] |
| 2025-04-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-18] |
| 2025-01-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-24] |
| 2024-12-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-12] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-21 | Hrt Financial Lp | sell | 49,710 | $0.69 | [4 2026-04-22] |
| 2026-04-20 | Hrt Financial Lp | sell | 94,462 | $0.75 | [4 2026-04-21] |
| 2026-04-17 | Hrt Financial Lp | buy | 34,636 | $0.73 | [4 2026-04-21] |
| 2026-04-16 | Hrt Financial Lp | sell | 53,867 | $0.73 | [4 2026-04-21] |
| 2026-04-15 | Hrt Financial Lp | buy | 92,554 | $0.76 | [4 2026-04-16] |
| 2026-04-14 | Hrt Financial Lp | buy | 74,350 | $0.77 | [4 2026-04-16] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | DEF 14A | Proxy statement |
| 2026-09-17 | PRE 14A | Proxy statement |
| 2026-09-14 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-09-08 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-31 | S-1/A | Registration statement |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-12 | S-1 | Registration statement |
| 2026-07-29 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-17 | 424B3 | Prospectus or prospectus supplement |
| 2026-06-09 | S-1 | Registration statement |
| 2026-05-19 | 8-K | Charter, bylaws or fiscal year change; Other events |
Alerts for $ONCO
Email me when Onconetix, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.